Adalimumab binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors. Upon binding to human TNF, Adalimumab either neutralizes the biological function of TNF by blocking its interaction with the cell surface TNF-receptors or modulates biological responses involving changes in leukocyte migration of adhesion molecules (ELAM-1, VCAM-1, and ICAM-1 with an IC50 of 0.1-0.2 nM). TNF plays a central role in initiation, maintenance and progression of several inflammatory diseases and treatment with Adalimumab improves the signs and symptoms of these TNF associated diseases in patients.


Exemptia™ should be administered subcutaneously.

Rheumatoid arthritis (RA)

  • The recommended dose in adult patients is 40 mg every other week. Patients with RA not receiving methotrexate may benefit from increasing the frequency to 40 mg every week. Drugs such as methotrexate, glucocorticoids, salicylates, non-steroidal antiinflammatory drugs, or analgesics can be continued during Adalimumab treatment.

Elderly patients

  • No dose adjustment is required

Impaired renal and/or hepatic function

  • Adalimumab has not been studied in these patients. No dose recommendations can be made.